DiaPlus Clinics - Diabetes Specialists
 
 
 
 
 
 
 
 
 For Appointments: click here
 
   Home      Interim Guidance for Clinicians on Identifying and Caring for Patients with Swine-origin Influenza A (H1N1) Virus Infection
 
DIABETES
 
DIABETES MELLITUS
 
TYPE 1 DM
 
TYPE 2 DM
 
GDM(PREGNENCY)
 
COMPLICATIONS OF DM
 
 
 
 
 
 
 
ONLINE FORUMS
 
 
 
 
 
 
PROMINENT DIABETES CLINICS
 
 
 
 
 
 
PROMINENT ENDOCRINOLOGISTS
 
 
 
 
 
ENDOCRINOLOGIST (DIABETALOGIST) IN BANGALORE
 

Interim Guidance for Clinicians on Identifying and Caring for Patients with Swine-origin Influenza A (H1N1) Virus Infection

 
 
 
 
 

Objective: This document provides interim guidance for clinicians who might provide care for patients with confirmed novel influenza A (H1N1) or suspected novel influenza A (H1N1) virus infection (previously referred to as swine-origin influenza virus). This document has changed as more ill persons have been identified and more epidemiologic and clinical information has been gathered. CDC recommends that testing be prioritized for those with severe respiratory illness and those at highest risk of complications from influenza, as reflected in this document.

Transmission

Transmission of novel influenza A (H1N1) is being studied as part of the ongoing outbreak investigation, but limited data available indicate that this virus is transmitted in ways similar to other influenza viruses. Seasonal human influenza viruses are thought to spread from person to person primarily through large-particle respiratory droplet transmission (e.g., when an infected person coughs or sneezes near a susceptible person). Transmission via large-particle droplets requires close contact between source and recipient persons because droplets do not remain suspended in the air and generally travel only a short distance (< 6 feet). Contact with contaminated surfaces is another possible source of transmission and transmission via droplet nuclei (also called “airborne” transmission). Because data on the transmission of novel H1N1 viruses are limited, the potential for ocular, conjunctival, or gastrointestinal infection is unknown. Since this is a novel influenza A virus in humans, transmission from infected persons to close contacts might be common. All respiratory secretions and bodily fluids (diarrheal stool) of novel influenza A (H1N1) cases should be considered potentially infectious.

Incubation period

The estimated incubation period is unknown and could range from 1-7 days, and more likely 1-4 days.

Persons with confirmed novel influenza A (H1N1) virus infection

View the Case definitions for Confirmed, Probable and Suspected cases.

Clinical findings

Patients with uncomplicated disease due to confirmed novel influenza A (H1N1) virus infection have experienced fever, chills, headache, upper respiratory tract symptoms (cough, sore throat, rhinorrhea, shortness of breath), myalgias, arthralgias, fatigue, vomiting, or diarrhea. In New York City, 95% of patients with novel influenza A (H1N1) met the case definition for influenza-like illness (subjective fever plus cough and/or sore throat) (Swine-Origin Influenza A (H1N1) Virus Infections in a School --- New York City, April 2009)

Complications

There is insufficient information to date about clinical complications of this novel influenza A (H1N1) virus infection. Among persons infected with previous variants of swine influenza viruses, clinical syndromes have ranged from mild respiratory illness, to lower respiratory tract illness, dehydration, or pneumonia. Deaths caused by previous variants of swine influenza viruses have occasionally occurred. Although data on the spectrum of illness is not yet available for this novel influenza A (H1N1), clinicians should expect complications to be similar to seasonal influenza: exacerbation of underlying chronic medical conditions, upper respiratory tract disease (sinusitis, otitis media, croup) lower respiratory tract disease (pneumonia, bronchiolitis, status asthmaticus), cardiac (myocarditis, pericarditis), musculoskeletal (myositis, rhabdomyolysis), neurologic (acute and post-infectious encephalopathy, encephalitis, febrile seizures, status epilepticus), toxic shock syndrome, and secondary bacterial pneumonia with or without sepsis.

Groups at high risk for complications

Currently, insufficient data are available to determine who is at higher risk for complications of novel influenza A (H1N1) virus infection. Thus, at this time, the same age and risk groups who are at higher risk for seasonal influenza complications should also be considered at higher risk for swine-origin influenza complications.

Groups at higher risk for seasonal influenza complications include:

  • Children less than 5 years old;
  • Persons aged 65 years or older;
  • Children and adolescents (less than 18 years) who are receiving long-term aspirin therapy and who might be at risk for experiencing Reye syndrome after influenza virus infection;
  • Pregnant women;
  • Adults and children who have chronic pulmonary, cardiovascular, hepatic, hematological, neurologic, neuromuscular, or metabolic disorders;
  • Adults and children who have immunosuppression (including immunosuppression caused by medications or by HIV);
  • Residents of nursing homes and other chronic-care facilities.

Medical care for patients with novel influenza A (H1N1) virus

Not all patients with suspected novel influenza (H1N1) infection need to be seen by a health care provider. Patients with severe illness and those at high risk for complications from influenza (see list above) should contact their medical provider or seek medical care.

Which patients should be tested for novel influenza A (H1N1) virus

Clinicians should test persons for the novel influenza (H1N1) virus if they have an acute febrile respiratory illness or sepsis-like syndrome. Certain groups may have atypical presentations including infants, elderly and persons with compromised immune systems. Priority for testing includes persons who 1) require hospitalization or 2) are at high-risk for severe disease (as listed above). To test for novel H1N1 influenza virus, upper respiratory specimens, such as a nasopharyngeal swab or aspirate, nasal swab plus a throat swab or nasal wash, or tracheal aspirate should be collected. Persons who perform nasal and tracheal aspirate collections on ill persons require appropriate personal protective equipment. Specimens should be sent to the state public health laboratory. Not all people with suspected novel influenza (H1N1) infection need to have the diagnosis confirmed, especially if the person resides in an affected area or if the illness is mild. Recommendations on who to test may differ by state or community. Clinicians should be aware of local guidance on testing and should use their clinical judgment in addition to this guidance for deciding when to test for novel influenza A (H1N1). View the Interim guidance on specimen collection, processing, and testing.

Reporting suspect novel influenza A (H1N1) virus infection

Clinicians should contact their state public health department if they test a person for novel influenza A (H1N1) infection to obtain information on what clinical and epidemiological data to collect and specimen shipment protocols in their state. See also Information on laboratory testing and specimen collection.

Treatment of novel influenza A (H1N1)

The novel influenza (H1N1) virus is susceptible to both oseltamivir and zanamivir. It is resistant to amantadine and rimantadine. View Interim guidance on antiviral treatment for novel influenza A (H1N1).

Additional Therapy

Additional therapy such as antibacterial agents, should be used at the discretion of the clinicians given the patients clinical presentation. For antibacterial treatment of pneumonia, clinical guidance for community-acquired pneumonia should be followed and can be accessed here.

For hospitalized patients with severe community-acquired pneumonia (CAP) requiring intensive care unit admission, menthicillin-resistent Staphylococcus aureus (MRSA) infection should be suspected and treated empirically in addition to other causes of CAP if they have 1) necrotizing or cavitary infiltrates or 2) empyema.

Infectious period

The duration of shedding with novel influenza A (h1N1) virus is unknown. Therefore, until data are available, the estimated duration of viral shedding is based upon seasonal influenza virus infection.. Infected persons are assumed to be shedding virus from one day prior to illness onset until resolution of symptoms. In general, persons with novel influenza A (H1N1) virus infection should be considered potentially infectious from one day before to 7 days following illness onset. Children, especially younger children, might be infectious for up to 10 days.

Infection control measures


View the guidance on infection control during care of patients with confirmed or suspected novel influenza A (H1N1) virus infection.

Antiviral chemoprophylaxis

View the guidance on pre-exposure and post-exposure chemoprophylaxis with antiviral agents for novel influenza A (H1N1) virus can be found at

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
PRACTICAL CORNER
 
 
DKA
 
HONK
 
 
WISDOM CORNER
 
PITFALLS
 
GET INSPIRED
 
CONTROVERSIES
 
 
 
FOR HEALTHCARE PROFESSIONALS
 
 
 
 
RELIGIOUS BELIEF

 
SWINE FLU
 
 
 
 
 COPYRIGHT© 2009 E DIABETES MELLITUS.COM
 
 
 
 
DR. PRAVEEN .R  
 
 
ediabetesmellitus@gmail.com, ediabetesmellitus@rediffmail.com.